Combination extends OS in metastatic colorectal cancer
Click Here to Manage Email Alerts
The addition of bevacizumab to trifluridine and tipiracil extended OS among patients with advanced colorectal cancer, according to a topline data announcement.
Trifluridine and tipiracil (Lonsurf; Taiho Oncology, Servier) is an oral agent that utilizes a dual mechanism of action to maintain clinical activity. Trifluridine, an antineoplastic nucleoside analogue, interferes with DNA function. The blood concentration of trifluridine is maintained via tipiracil, an inhibitor of the trifluridine-degrading enzyme thymidine phosphorylase.
The randomized phase 3 SUNLIGHT trial included 492 patients with refractory metastatic colorectal cancer who had received two chemotherapy regimens.
Researchers assigned patients 1:1 to trifluridine and tipiracil alone or with bevacizumab (Avastin, Genentech).
The trial met its primary endpoint, demonstrating superiority of trifluridine and tipiracil plus bevacizumab with regard to OS. Key secondary endpoints included PFS, overall response rate, disease control rate, quality of life, safety and tolerability.
Complete results of the SUNLIGHT trial will be presented at a scientific conference.
“Findings from the SUNLIGHT trial could potentially represent a significant advancement in the treatment of patients with metastatic colorectal cancer who have progressed after two lines of standard chemotherapy,” Nadia Caussé-Amellal, MD, head of global development for gastrointestinal indications in the oncology and immuno-oncology therapeutic area with Servier, said in a press release. “Combining [trifluridine and tipiracil] with bevacizumab demonstrated the potential to extend survival [for] these patients who have limited therapeutic options.”
Click Here to Manage Email Alerts